InMed Pharmaceuticals Inc.
InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.
InMed is utilizing its proprietary bioinformatics assessment tool to dentify cannabinoid compounds, or combinations thereof, that have therapeutic potential in diseases with high unmet medical needs. The goal is to identify new drug candidates that optimize therapeutic benefit while limiting adverse effects.
InMed’s proprietary in silico drug/disease bioinformatics assessment tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company.
InMed Pharmaceuticals Inc. (IN)
Communiqués de presse
Le 23 mars/March 2018
The common shares of InMed Pharmaceuticals Inc. will be delisted at the market close today, March 23, 2018.
InMed Pharmaceuticals Inc. will continue to trade on the Toronto Stock Exchange.
Les actions ordinaires d'InMed Pharmaceuticals Inc. seront radiées à la clôture des marchés le 23 mars 2018.
InMed Pharmaceuticals Inc. continuera de négocier à la Bourse de Toronto.